Skip to main content
Top

05-06-2024 | Hepatocellular Carcinoma | News

ASCO 2024

Dual immunotherapy with nivolumab plus ipilimumab improves overall survival of unresectable hepatocellular carcinoma

MedNet.nl: Compared with the TKIs lenvatinib or sorafenib, dual immunotherapy with nivolumab plus ipilimumab improves overall survival in patients with unresectable advanced hepatocellular carcinoma. The results are from the CheckMate 9DW study.

Related topics